A carregar...

Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells

The gradual emerging of resistance to imatinib urgently calls for the development of new therapy for chronic myeloid leukemia (CML). The fusion protein Bcr-Abl, which promotes the malignant transformation of CML cells, is mainly located in the cytoplasm, while the c-Abl protein which is expressed in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int J Mol Sci
Main Authors: Li, Qianyin, Huang, Zhenglan, Gao, Miao, Cao, Weixi, Xiao, Qin, Luo, Hongwei, Feng, Wenli
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5372553/
https://ncbi.nlm.nih.gov/pubmed/28257089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18030537
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!